Business Areas

Global, Full-Scale Services

OEP’s growth strategy is focused on four main lines of business.

Licensing and Distribution of Branded Pharma in Asia

OEP has been the commercial partner of choice for global pharmaceutical companies for nearly 40 years.


ANDAs

OEP partners with commercial distributors to manufacture and market products in the U.S. and  other select markets.

Microscope-1
Co-development of 505(b)(2)s

Partners rely on our financial means, technology, and manufacturing capacity to co-develop and launch 505(b)(2)s.


CMO/CDMO Services

Our state-of-the art facilities are TAA-compliant and USFDA-certified (or will soon receive certification).

Licensing and Distribution of Branded Pharma in Asia

With nearly 40 years of local regulatory and sales expertise, and 350+person sales teams in 7 countries, OEP delivers top sales results in our countries of operation.

Co-Development of 505(b)(2)s

Specialty Pharma is a priority at OEP. Partners rely on our financial means, technology, and manufacturing capacity to efficiently bring 505(b)(2)s to market. 

ANDAs

Over the last 10 years, OEP has developed a growing generics portfolio. We partner with commercial distributors to market our products in the U.S. and other select markets.

CMO/CDMO Services 

Our FDA-certified, PIC/S GMP facility produces medicines at formulations and quantities that can be tailored for each stage, from trial to commercial production. All products are made in Taiwan, a TAA-compliant country. We offer CMO/CDMO as part of a packaged suite, or as a standalone service.